Fig. 7: Effects of VEN treatment in PDX models. | Cell Death Discovery

Fig. 7: Effects of VEN treatment in PDX models.

From: Effective tumor cell abrogation via Venetoclax-mediated BCL-2 inhibition in KMT2A-rearranged acute B-lymphoblastic leukemia

Fig. 7

Analysis of one to three individual animals per PDX model and intervention group. A Tumor cell proliferation of KMT2A (upper panel) and BCR::ABL1 rearranged models was monitored by peripheral blood (PB) blast frequency measurement via flow cytometry (CD45+/CD19+). Each line represents an individual animal. Dotted lines represent the start and end date of the treatment interval. B Determination of blast frequency in PB, bone marrow (BM), and spleen by flow cytometry after experiment termination. Control and VEN-treated mice of all KMT2A (upper graph) or BCR::ABL1 rearranged models are summarized. Each dot represents an individual animal. Mean ± SD, unpaired t-test with Welch’s correction or Mann–Whitney test. C Box plots (min/max) of spleen length, weight, and cell count of KMT2A (upper panel) and BCR::ABL1 rearranged models. Controls and VEN-treated mice of all models per cytogenetic subtype are summarized. Each dot represents an individual animal. Mann–Whitney test. D Representative images of blast morphology of KMT2A (left panel) and BCR::ABL1 rearranged PDX models treated with vehicle or VEN. Pappenheim staining of bone marrow cells. 100-fold magnification.

Back to article page